Analystreport

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Zacks Investment Research. They now have a $191.00 price target on the stock.

Vertex Pharmaceuticals Incorporated  (VRTX) 
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com